Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXR Daxor	$7.30 +1.4%	$7.77	$6.55 ▼ $10.00	$35.31M	-0.21	6,570 shs	5,219 shs
LUCD Lucid Diagnostics	$1.28 +7.6%	$1.36	$0.68 ▼ $1.80	$134.89M	1.28	494,952 shs	1.54 million shs
LUNG Pulmonx	$3.26 -1.8%	$5.66	$3.18 ▼ $9.41	$131.24M	0.65	311,721 shs	391,454 shs
ZJYL Jin Medical International	$0.64 -24.9%	$0.79	$0.56 ▼ $4.38	$99.53M	12.24	294,512 shs	957,554 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXR Daxor	-0.83%	-4.89%	-10.56%	+2.13%	-22.66%
LUCD Lucid Diagnostics	+8.18%	-3.25%	+1.71%	-10.53%	+25.26%
LUNG Pulmonx	-9.78%	-3.21%	-36.76%	-52.64%	-62.14%
ZJYL Jin Medical International	-5.71%	+2.05%	+15.87%	+4.89%	-74.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXR Daxor	4.2958 of 5 stars	3.5	5.0	0.0	0.0	2.4	3.3	0.0
LUCD Lucid Diagnostics	3.0419 of 5 stars	3.6	5.0	0.0	0.0	2.0	1.7	0.6
LUNG Pulmonx	3.7052 of 5 stars	4.4	3.0	0.0	0.0	3.6	2.5	0.6
ZJYL Jin Medical International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXR Daxor	3.00	Buy	$25.00	242.47% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.50	173.44% Upside
LUNG Pulmonx	2.78	Moderate Buy	$12.07	270.29% Upside
ZJYL Jin Medical International	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest DXR, LUNG, ZJYL, and LUCD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
3/26/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
3/25/2025	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/24/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.50 ➝ $3.00
3/17/2025	DXR Daxor	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.75 ➝ $25.00
3/10/2025	LUNG Pulmonx	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXR Daxor	$2.13M	16.57	N/A	N/A	N/A	∞
LUCD Lucid Diagnostics	$4.35M	31.04	N/A	N/A	($0.47) per share	-2.72
LUNG Pulmonx	$87.47M	1.50	N/A	N/A	$3.09 per share	1.06
ZJYL Jin Medical International	$23.50M	4.24	$0.02 per share	31.44	$0.18 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXR Daxor	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	-$52.67M	-$1.08	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	5/14/2025 (Estimated)
LUNG Pulmonx	-$60.84M	-$1.44	N/A	N/A	N/A	-67.31%	-55.36%	-33.53%	7/29/2025 (Estimated)
ZJYL Jin Medical International	$3.68M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest DXR, LUNG, ZJYL, and LUCD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	LUCD Lucid Diagnostics	-$0.13	-$0.17	-$0.04	-$0.66	$1.30 million	N/A
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million
2/19/2025	Q4 2024	LUNG Pulmonx	-$0.45	-$0.33	+$0.12	-$0.33	$22.29 million	$23.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXR Daxor	$0.03	0.41%	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
ZJYL Jin Medical International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXR Daxor	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	1.18	1.14
LUNG Pulmonx	0.40	7.70	6.77
ZJYL Jin Medical International	N/A	2.50	2.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXR Daxor	1.34%
LUCD Lucid Diagnostics	74.01%
LUNG Pulmonx	91.04%
ZJYL Jin Medical International	N/A

Insider Ownership

Company	Insider Ownership
DXR Daxor	59.00%
LUCD Lucid Diagnostics	8.80%
LUNG Pulmonx	6.80%
ZJYL Jin Medical International	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXR Daxor	37	4.84 million	1.98 million	Not Optionable
LUCD Lucid Diagnostics	70	105.38 million	54.12 million	No Data
LUNG Pulmonx	250	40.26 million	37.24 million	Optionable
ZJYL Jin Medical International	245	156.55 million	N/A	Not Optionable

DXR, LUNG, ZJYL, and LUCD Headlines

Recent News About These Companies

Jin Medical International (NASDAQ:ZJYL) Stock Price Up 5% - Time to Buy?

May 8, 2025 | marketbeat.com

Jin Medical Faces Nasdaq Listing Compliance Challenge

May 6, 2025 | tipranks.com

Jin Medical International Ltd. -- Nasdaq Minimum Bid Price Non-Compliance

May 6, 2025 | gurufocus.com

Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance

May 6, 2025 | globenewswire.com

Jin Medical International (NASDAQ:ZJYL) Trading 5% Higher - What's Next?

May 6, 2025 | americanbankingnews.com

Is Jin Medical International Ltd.'s (NASDAQ:ZJYL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

April 28, 2025 | finance.yahoo.com

Jin Medical Boosts Production Capacity with New Chuzhou Facility

April 25, 2025 | tipranks.com

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

April 13, 2025 | nasdaq.com

Why Jin Medical International Ltd.’s (ZJYL) Stock Is Down 12.45%

April 3, 2025 | aaii.com

Why Jin Medical International Ltd.’s (ZJYL) Stock Is Up 10.09%

March 25, 2025 | aaii.com

Why Jin Medical International Ltd.’s (ZJYL) Stock Is Down 29.03%

March 22, 2025 | aaii.com

Why Jin Medical International Ltd.’s (ZJYL) Stock Is Up 14.61%

March 20, 2025 | aaii.com

Why Jin Medical International Ltd.’s (ZJYL) Stock Is Up 11.29%

January 31, 2025 | aaii.com

Jin Medical International Full Year 2024 Earnings: EPS: US$0.023 (vs US$0.02 in FY 2023)

January 27, 2025 | finance.yahoo.com

Wuhan Jin Jiang International Hotel

November 12, 2024 | travelweekly.com

Jin of BTS fronts rock band in 'I'll Be There' music video

October 25, 2024 | msn.com

Construction of JinMed's New Facility Begins in Chuzhou, China

October 10, 2024 | globenewswire.com

Some Investors May Be Worried About Jin Medical International's (NASDAQ:ZJYL) Returns On Capital

October 9, 2024 | finance.yahoo.com

ZJYL Sees a Stock Surge of 5.04% Amid Positive Financial Performance

October 2, 2024 | gurufocus.com

Crude Oil Down Over 1%; US Manufacturing PMI Falls In September

September 24, 2024 | msn.com

United States shares mixed at close of trade; Dow Jones Industrial Average up 0.09%

September 21, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
2 Smart Investments to Follow Warren Buffett’s Lead
By Ryan Hasson | April 23, 2025
View 2 Smart Investments to Follow Warren Buffett’s Lead
PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy
By Thomas Hughes | April 28, 2025
View PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy

DXR, LUNG, ZJYL, and LUCD Company Descriptions

Daxor NASDAQ:DXR

$7.30 +0.10 (+1.39%)

As of 01:19 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Lucid Diagnostics NASDAQ:LUCD

$1.28 +0.09 (+7.56%)

As of 04:00 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Pulmonx NASDAQ:LUNG

$3.26 -0.06 (-1.81%)

As of 04:00 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Jin Medical International NASDAQ:ZJYL

$0.64 -0.21 (-24.94%)

As of 04:00 PM Eastern

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time